Estonya - Estonca - Ravimiamet

dne pharma as - levometadoon - suukaudne lahus üheannuselises konteineris - 40mg 7tk; 40mg 1tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

substipharm - raloksifeen vesinikkloriid - osteoporoos, postmenopausis - suguhormoonid ja genitaalsüsteemi, - evista on näidustatud menopausijärgsetel naistel osteoporoosi raviks ja ennetamiseks. on tõestatud selgroolüli, kuid mitte puusaluu murdude esinemissageduse olulist vähenemist. when determining the choice of evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

novartis europharm limited - trametiniib - melanoom - antineoplastilised ained - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. mitteväikerakk-kopsuvähk (mitteväikerakk-kopsuvähi)trametinib koos dabrafenib on näidustatud ravi täiskasvanud patsientidel, kaugelearenenud mitteväikerakk-kopsuvähi, mille braf v600 mutatsioon.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - hiv-nakkused - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta on näidustatud koos teiste retroviirusevastaste ravimitega inimese immuunpuudulikkuse viiruse 1 (hiv 1) nakkuse raviks 18-aastastel ja vanematel täiskasvanutel. genotypic katsetamine peaks juhendi kasutamine rezolsta.

Estonya - Estonca - Ravimiamet

glaxosmithkline (ireland) limited - lamotrigiin - närimis-/dispergeeruv tablett - 5mg 56tk; 5mg 50tk; 5mg 42tk; 5mg 60tk; 5mg 10tk

Estonya - Estonca - Ravimiamet

glaxosmithkline (ireland) limited - lamotrigiin - närimis-/dispergeeruv tablett - 100mg 200tk; 100mg 42tk; 100mg 10tk; 100mg 30tk; 100mg 98tk; 100mg 14tk; 100mg 56tk

Estonya - Estonca - Ravimiamet

glaxosmithkline (ireland) limited - lamotrigiin - närimis-/dispergeeruv tablett - 50mg 50tk; 50mg 90tk; 50mg 200tk; 50mg 10tk; 50mg 60tk; 50mg 98tk; 50mg 14tk; 50mg 100tk; 50mg 28tk

Estonya - Estonca - Ravimiamet

glaxosmithkline (ireland) limited - lamotrigiin - närimis-/dispergeeruv tablett - 25mg 42tk; 25mg 14tk; 25mg 30tk; 25mg 28tk; 25mg 56tk

Estonya - Estonca - Ravimiamet

glaxosmithkline (ireland) limited - lamotrigiin - närimis-/dispergeeruv tablett - 2mg 30tk